Wounds - Pipeline Review, H1 2017 - Product Image

Wounds - Pipeline Review, H1 2017

  • ID: 4311823
  • Report
  • 186 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AlgiPharma AS
  • Beech Tree Labs Inc
  • CorMedix Inc
  • FibroGen Inc
  • Novan Inc
  • RXi Pharmaceuticals Corp
  • MORE
Wounds - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H1 2017, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 58, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 7 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AlgiPharma AS
  • Beech Tree Labs Inc
  • CorMedix Inc
  • FibroGen Inc
  • Novan Inc
  • RXi Pharmaceuticals Corp
  • MORE
  1. Introduction
  2. Wounds - Overview
  3. Wounds - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Wounds - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Wounds - Companies Involved in Therapeutics Development
  15. AlgiPharma AS
  16. Alliance Pharma Plc
  17. AmpliPhi Biosciences Corp
  18. AndroScience Corp
  19. Anterogen Co Ltd
  20. Aridis Pharmaceuticals LLC
  21. Beech Tree Labs Inc
  22. Bio3 Research Srl
  23. Biotec Pharmacon ASA
  24. Blueberry Therapeutics Ltd
  25. Cellphire Inc
  26. Chiesi Farmaceutici SpA
  27. CorMedix Inc
  28. Dermala Inc
  29. Destiny Pharma Ltd
  30. Escape Therapeutics Inc
  31. EyeGene Inc
  32. FibroGen Inc
  33. Foresee Pharmaceuticals LLC
  34. Gene Signal International SA
  35. GlaxoSmithKline Plc
  36. IC-MedTech Inc
  37. Living Cell Technologies Ltd
  38. Madam Therapeutics BV
  39. miRagen Therapeutics Inc
  40. NatureWise Biotech & Medicals Corp
  41. Novan Inc
  42. Octapharma AG
  43. Omeros Corp
  44. Osiris Therapeutics Inc
  45. Pacific Northwest Biotechnology LLC
  46. ProMetic Life Sciences Inc
  47. RMB-Research GmbH
  48. RXi Pharmaceuticals Corp
  49. SomaGenics Inc
  50. Stratatech Corp
  51. Synedgen Inc
  52. Thesan Pharmaceuticals Inc
  53. Topadur Pharma AG
  54. Traverse Biosciences Inc
  55. Tumorend LLC
  56. Vascular BioSciences
  57. viDA Therapeutics Inc
  58. Wounds - Drug Profiles
  59. (cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
  60. A-3APO - Drug Profile
  61. ABSA-01 - Drug Profile
  62. AGL-110 - Drug Profile
  63. ALLO-ASC - Drug Profile
  64. AlloGraf - Drug Profile
  65. Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile
  66. APO-1 - Drug Profile
  67. APO-2 - Drug Profile
  68. AR-101 - Drug Profile
  69. Arginine Butyrate - Drug Profile
  70. ARN-077 - Drug Profile
  71. ASCJ-9 - Drug Profile
  72. AyuV-25 - Drug Profile
  73. B-244 - Drug Profile
  74. BB-1000 - Drug Profile
  75. BDM-I - Drug Profile
  76. BTL-slo - Drug Profile
  77. CAR Peptide - Drug Profile
  78. Cell Therapy for Dermatology and Immunology - Drug Profile
  79. CM-101 - Drug Profile
  80. CRMD-004 - Drug Profile
  81. CTR-2 - Drug Profile
  82. daprodustat - Drug Profile
  83. DB-2121 - Drug Profile
  84. Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile
  85. Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile
  86. Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile
  87. EGS-001 - Drug Profile
  88. FG-6874 - Drug Profile
  89. FP-025 - Drug Profile
  90. G-3KL - Drug Profile
  91. Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
  92. Gene Therapy to Activate HSP60 for Wounds - Drug Profile
  93. GS-156 - Drug Profile
  94. Human Growth Factor - Drug Profile
  95. hVGF - Drug Profile
  96. JM-2 CR - Drug Profile
  97. LWnt-3a - Drug Profile
  98. MG-53 - Drug Profile
  99. MMP-26051 - Drug Profile
  100. MMP-26052 - Drug Profile
  101. molgramostim - Drug Profile
  102. Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
  103. MRG-110 - Drug Profile
  104. NBM-67 - Drug Profile
  105. ND-336 - Drug Profile
  106. NTCELL - Drug Profile
  107. Oligomer G for Burn Wounds - Drug Profile
  108. OTI-1011 - Drug Profile
  109. OTI-1502 - Drug Profile
  110. P-148 - Drug Profile
  111. Panaecin - Drug Profile
  112. Peptides for Wounds - Drug Profile
  113. Perlecan - Drug Profile
  114. PGF - Drug Profile
  115. plasminogen (recombinant) - Drug Profile
  116. Polysaccharide for Wounds and Scars - Drug Profile
  117. Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile
  118. Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile
  119. Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
  120. Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile
  121. Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile
  122. Recombinant Protein to Agonize FGFR2 for Wounds - Drug Profile
  123. Recombinant Protein to Agonize NGFR for Wounds - Drug Profile
  124. Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
  125. Recombinant Protein to Target MMP-9 for Wounds - Drug Profile
  126. Recombinant Proteins for Diabetic Wound Healing - Drug Profile
  127. RT-1740 - Drug Profile
  128. SFR-9X0125 - Drug Profile
  129. SG-404 - Drug Profile
  130. silver sulfadiazine - Drug Profile
  131. Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile
  132. Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile
  133. Small Molecule to Target LGR6 for Dermatology - Drug Profile
  134. Small Molecules for Staphylococcal Infections and Wounds - Drug Profile
  135. Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile
  136. Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
  137. Soluble Beta Glucan - Drug Profile
  138. Statmicoll - Drug Profile
  139. Stm Cell Therapy for Chronic Wounds - Drug Profile
  140. Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile
  141. Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile
  142. Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile
  143. Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
  144. Thrombosomes - Drug Profile
  145. Tolecine - Drug Profile
  146. TOPN-53 - Drug Profile
  147. TRBN-0224 - Drug Profile
  148. TWB-103 - Drug Profile
  149. V-2248 - Drug Profile
  150. VTI-3000 Series - Drug Profile
  151. WH-1 - Drug Profile
  152. XF-70 - Drug Profile
  153. Wounds - Dormant Projects
  154. Wounds - Discontinued Products
  155. Wounds - Product Development Milestones
  156. Featured News & Press Releases
  157. Appendix
  158. Methodology
  159. Coverage
  160. Secondary Research
  161. Primary Research
  162. Expert Panel Validation
  163. Contact Us
  164. Disclaimer
List of Tables:
  1. Number of Products under Development for Wounds, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Companies, H1 2017 (Contd..1), H1
  4. Number of Products under Development by Companies, H1 2017 (Contd..2), H1
  5. Number of Products under Development by Companies, H1 2017 (Contd..3), H1
  6. Number of Products under Development by Universities/Institutes, H1
  7. Products under Development by Companies, H1
  8. Products under Development by Companies, H1 2017 (Contd..1), H1
  9. Products under Development by Companies, H1 2017 (Contd..2), H1
  10. Products under Development by Companies, H1 2017 (Contd..3), H1
  11. Products under Development by Universities/Institutes, H1
  12. Number of Products by Stage and Target, H1
  13. Number of Products by Stage and Target, H1 2017 (Contd..1), H1
  14. Number of Products by Stage and Mechanism of Action, H1
  15. Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1
  16. Number of Products by Stage and Route of Administration, H1
  17. Number of Products by Stage and Molecule Type, H1
  18. Wounds - Pipeline by AlgiPharma AS, H1
  19. Wounds - Pipeline by Alliance Pharma Plc, H1
  20. Wounds - Pipeline by AmpliPhi Biosciences Corp, H1
  21. Wounds - Pipeline by AndroScience Corp, H1
  22. Wounds - Pipeline by Anterogen Co Ltd, H1
  23. Wounds - Pipeline by Aridis Pharmaceuticals LLC, H1
  24. Wounds - Pipeline by Beech Tree Labs Inc, H1
  25. Wounds - Pipeline by Bio3 Research Srl, H1
  26. Wounds - Pipeline by Biotec Pharmacon ASA, H1
  27. Wounds - Pipeline by Blueberry Therapeutics Ltd, H1
  28. Wounds - Pipeline by Cellphire Inc, H1
  29. Wounds - Pipeline by Chiesi Farmaceutici SpA, H1
  30. Wounds - Pipeline by CorMedix Inc, H1
  31. Wounds - Pipeline by Dermala Inc, H1
  32. Wounds - Pipeline by Destiny Pharma Ltd, H1
  33. Wounds - Pipeline by Escape Therapeutics Inc, H1
  34. Wounds - Pipeline by EyeGene Inc, H1
  35. Wounds - Pipeline by FibroGen Inc, H1
  36. Wounds - Pipeline by Foresee Pharmaceuticals LLC, H1
  37. Wounds - Pipeline by Gene Signal International SA, H1
  38. Wounds - Pipeline by GlaxoSmithKline Plc, H1
  39. Wounds - Pipeline by IC-MedTech Inc, H1
  40. Wounds - Pipeline by Living Cell Technologies Ltd, H1
  41. Wounds - Pipeline by Madam Therapeutics BV, H1
  42. Wounds - Pipeline by miRagen Therapeutics Inc, H1
  43. Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H1
  44. Wounds - Pipeline by Novan Inc, H1
  45. Wounds - Pipeline by Octapharma AG, H1
  46. Wounds - Pipeline by Omeros Corp, H1
  47. Wounds - Pipeline by Osiris Therapeutics Inc, H1
  48. Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H1
  49. Wounds - Pipeline by ProMetic Life Sciences Inc, H1
  50. Wounds - Pipeline by RMB-Research GmbH, H1
  51. Wounds - Pipeline by RXi Pharmaceuticals Corp, H1
  52. Wounds - Pipeline by SomaGenics Inc, H1
  53. Wounds - Pipeline by Stratatech Corp, H1
  54. Wounds - Pipeline by Synedgen Inc, H1
  55. Wounds - Pipeline by Thesan Pharmaceuticals Inc, H1
  56. Wounds - Pipeline by Topadur Pharma AG, H1
  57. Wounds - Pipeline by Traverse Biosciences Inc, H1
  58. Wounds - Pipeline by Tumorend LLC, H1
  59. Wounds - Pipeline by Vascular BioSciences, H1
  60. Wounds - Pipeline by viDA Therapeutics Inc, H1
  61. Wounds - Dormant Projects, H1
  62. Wounds - Dormant Projects, H1 2017 (Contd..1), H1
  63. Wounds - Dormant Projects, H1 2017 (Contd..2), H1
  64. Wounds - Dormant Projects, H1 2017 (Contd..3), H1
  65. Wounds - Dormant Projects, H1 2017 (Contd..4), H1
  66. Wounds - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Wounds, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Top 10 Targets, H1
  5. Number of Products by Stage and Top 10 Targets, H1
  6. Number of Products by Top 10 Mechanism of Actions, H1
  7. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Top 10 Molecule Types, H1
  11. Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AlgiPharma AS
  • Alliance Pharma Plc
  • AmpliPhi Biosciences Corp
  • AndroScience Corp
  • Anterogen Co Ltd
  • Aridis Pharmaceuticals LLC
  • Beech Tree Labs Inc
  • Bio3 Research Srl
  • Biotec Pharmacon ASA
  • Blueberry Therapeutics Ltd
  • Cellphire Inc
  • Chiesi Farmaceutici SpA
  • CorMedix Inc
  • Dermala Inc
  • Destiny Pharma Ltd
  • Escape Therapeutics Inc
  • EyeGene Inc
  • FibroGen Inc
  • Foresee Pharmaceuticals LLC
  • Gene Signal International SA
  • GlaxoSmithKline Plc
  • IC-MedTech Inc
  • Living Cell Technologies Ltd
  • Madam Therapeutics BV
  • miRagen Therapeutics Inc
  • NatureWise Biotech & Medicals Corp
  • Novan Inc
  • Octapharma AG
  • Omeros Corp
  • Osiris Therapeutics Inc
  • Pacific Northwest Biotechnology LLC
  • ProMetic Life Sciences Inc
  • RMB-Research GmbH
  • RXi Pharmaceuticals Corp
  • SomaGenics Inc
  • Stratatech Corp
  • Synedgen Inc
  • Thesan Pharmaceuticals Inc
  • Topadur Pharma AG
  • Traverse Biosciences Inc
  • Tumorend LLC
  • Vascular BioSciences
  • viDA Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll